Skip to main content
Publications
Rebordosa C , Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J , Bothner U, Rothman KJ , Zint K, Mines DI , Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists . Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study . Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Fortuny J , Gilsenan AW , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J , Flynn RW, Plana E , Ziemiecki R , Andrews EB, Gilsenan A . Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B , Bui C , Arana A , Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S . Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany . Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):953-61. doi: 10.1002/pds.4584
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E , Rasmussen L, Bizouard G, Forns J , Hellfritzsch M, Zint K, Perez-Gutthann S , Pladevall-Vila M . Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: a case study of dabigatran etexilate in Europe . Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):713-23. doi: 10.1002/pds.4416
Castellsague J, Calingaert B , Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Arana A , Bui C , Laguna C, Prados-Torres A, Roso-Llorach A, Perez-Gutthann S . Impact of risk minimization measures on the use of cilostazol in Europe . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):428. doi: 10.1002/pds
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E , Rasmussen L, Bizouard G, Forns J , Hellfritzsch M, Zint K, Perez-Gutthann S , Pladevall-Vila M . Evaluation of potential off-label prescribing of dabigatran etexilate in France, Denmark, and the United Kingdom and associated methodological challenges . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):566. doi: 10.1002/pds
Castellsague J, Perez-Gutthann S , Calingaert B , Bui C , Varas-Lorenzo C, Arana A , Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany . Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):615-24. doi: 10.1002/pds.4167
Zografos LJ , Suzart K, Horvat-Broecker A, Soriano-Gabarro M, Wolin DL , Calingaer B , Davenport EK , Hollis KA , Andrews E. Evaluating physician knowledge of risks and safe use of Xarelto (rivaroxaban) . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):288-9.
Castellsague J, Calingaert B , Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A , Bui C , Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthann S . Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):203-4.
McGrath LJ, Rulgomez A, Plana E , Fortuny J , Garcia-Rodriguez L, Rebordosa C , Varas-Lorenzo C, Ziemiecki R , Gilsenan AW , Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Plana E , McGrath LJ, Fortuny J , Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW , Andrews E, Rebordosa C , Ziemiecki R . An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds
Masclee GMC, Valkoff VE, Straatman H, Herings R, Garbe E, Schink T, Kollhorst B, Arfe A, Lucchi S, Villa M, Castellsague J, Perez-Gutthann S , Varas-Lorenzo C, Schade R, Schuemie M, Vergouwe Y, Steyerberg E, Sturkenboom M, Romio S. Individualized NSAID prescribing based on gastrointestinal and cardiovascular risks: a decision model in the SOS project . Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):36-7. doi: 10.1002/pds.3838
Afonso ASM, Schmiedl S, Becker C, Primatesta P, Plana E , Souverin PC, Korevaar JC, Hasford J, Reynolds R, de Groot MCH, Schlienger RG, Klungel OH, Rottenkolber M. Association between inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction: a methodological comparison of two databases . Poster presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 2014. Taipei, China. [abstract] Pharmacoepidemiol Drug Saf. 2014 Oct; 23(S1):390-1.
Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, Lewis J, Mines D , Barrett JS, Bilker W, Strom BL. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network . Pharmacoepidemiol Drug Saf. 2012 May;21(5):494-506. doi: 10.1002/pds.3199